Evidence map›Paper›PMID 24457189›Full record

ReviewThe Lancet. Neurology2014

Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.

Sophia Varadkar, Christian G Bien, Carol A Kruse, Frances E Jensen, Jan Bauer, Carlos A Pardo, Angela Vincent, Gary W Mathern, J Helen Cross

Open access · greenAbstract readReview
In one paragraph

Review in The Lancet. Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 199 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 2 pooled it
22.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 2 syntheses or guidelines pooled it, 457 citations in OpenAlex.

  1. Guideline
  2. BrainEuropean journal of nuclear medicine and molecular imaging · 2021
    Pooled it
  3. Suspected encephalitis in adults.Practical neurology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The role of early immunotherapy in rasmussen's encephalitis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  17. Article
  18. A case report: Neuropsychiatric presentation of atypical Rasmussen's encephalitis.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2026
    Article
  19. Article
  20. Article

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 4 countries.

Sophia VaradkarEpilepsy Unit, Great Ormond Street Hospital for Children NHS Foundation Trust and UCL Institute of Child Health, London, UK. Electronic address: sophia.varadkar@gosh.nhs.uk.
Christian G BienEpilepsy Centre Bethel, Krankenhaus Mara, Bielefeld, Germany.
Carol A KruseDepartment of Neurosurgery, Brain Research Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Frances E JensenDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, PA, USA.
Jan BauerDepartment of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Vienna, Austria.
Carlos A PardoDepartment of Neurology and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Angela VincentNuffield Department of Clinical Neurosciences, University of Oxford, UK.
Gary W MathernDepartments of Neurosurgery and Psychiatry and Biobehavioral Medicine, David Geffen School of Medicine, Mattel Children's Hospital, University of California, Los Angeles, CA, USA.
J Helen CrossNeurosciences Unit, UCL Institute of Child Health, Great Ormond Street Hospital for Children NHS Foundation Trust, London, and Young Epilepsy, Lingfield, UK.
Great Ormond Street Hospital for Children NHS Foundation Trust · GBBethel University · USJohns Hopkins University · USMattel Children's Hospital · USMedical University of Vienna · ATUniversity of California, Los Angeles · USUniversity of Oxford · GBUniversity of Pennsylvania · US

Funding

PATHOPHYSIOLOGY OF DEVELOPING DYSPLASTIC HUMAN CORTEXR01NS038992 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CEPEDA, CARLOS T, MATHERN, GARY W. · 1999 to 2013
$3.3M
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent GliomasR01CA125244 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIAU, LINDA M · 2010 to 2014
$2.4M
Optimizing Induction Conditions for Immunotherapeutic CTLR01CA154256 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PRINS, ROBERT M · 2010 to 2014
$1.9M
NCI NIH HHS NIH RO1CA125244-01A2NCI NIH HHS R01 CA125244NCI NIH HHS R01 CA154256NCI NIH HHS R01CA154256NINDS NIH HHS NIH RO1NS38992NINDS NIH HHS R01 NS038992
6 · The paper itself

Abstract

Rasmussen's encephalitis is a rare chronic neurological disorder, characterised by unilateral inflammation of the cerebral cortex, drug-resistant epilepsy, and progressive neurological and cognitive deterioration. Neuropathological and immunological studies support the notion that Rasmussen's encephalitis is probably driven by a T-cell response to one or more antigenic epitopes, with potential additional contribution by autoantibodies. Careful analysis of the association between histopathology and clinical presentation suggests that initial damage to the brain is mediated by T cells and microglia, suggesting a window for treatment if Rasmussen's encephalitis can be diagnosed early. Advances in neuroimaging suggest that progression of the inflammatory process seen with MRI might be a good biomarker in Rasmussen's encephalitis. For many patients, families, and doctors, choosing the right time to move from medical management to surgery is a real therapeutic dilemma. Cerebral hemispherectomy remains the only cure for seizures, but there are inevitable functional compromises. Decisions of whether or when surgery should be undertaken are challenging in the absence of a dense neurological deficit, and vary by institutional experience. Further, the optimum time for surgery, to give the best language and cognitive outcome, is not yet well understood. Immunomodulatory treatments seem to slow rather than halt disease progression in Rasmussen's encephalitis, without changing the eventual outcome.

Indexed as

EncephalitisHumans

Identifiers

PMID24457189
PMCPMC4005780
OpenAlexW2014778415

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.